---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-227975"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:10:59.949666+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Verrica CFO Terence Kohler resigns effective Oct 4, 2024

## Summary
- CFO Terence Kohler notified company of resignation on Sep 23, 2024.
- Resignation effective October 4, 2024; Kohler leaving to pursue new business opportunity.
- No successor or interim CFO named; CEO Ted White signs the filing.

## SEC filing metadata
- accession: 0001193125-24-227975
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312524227975/0001193125-24-227975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312524227975/d834736d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-227975
- JSON: https://secwatch.observer/filing/0001193125-24-227975.json
- Plain text: https://secwatch.observer/filing/0001193125-24-227975.txt

## Key facts
- Executive change
  Terence Kohler resigned as Chief Financial Officer at Verrica Pharmaceuticals Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On September 23, 2024, Terence Kohler, Chief Financial Officer of the Company, notified the Company of his resignation from his position, effective October 4, 2024 (the “Separation Date”), to pursue a new business opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312524227975/0001193125-24-227975-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.